Dermata Therapeutics
DRMA
5 hedge funds and large institutions have $78.3K invested in Dermata Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
163% more capital invested
Capital invested by funds: $29.8K → $78.3K (+$48.4K)
0.74% more ownership
Funds ownership: 0.01% → 0.74% (+0.74%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$122K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.44K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$8.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.03K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.92K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $66.9K | +$122K | +2,800 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4.14K | +$5.87K | +135 | +355% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.08K | +$7.44K | +171 | New |
|
4
Acadian Asset Management
Boston,
Massachusetts
| $3K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $108 | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $7 | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$8.2K | -133 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$7.03K | -117 | Closed |
|
|
9
Geode Capital Management
Boston,
Massachusetts
| – | -$4.92K | -82 | Closed |
|
|
10
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$6 | – | – |
|
DRMA Hedge Fund Activity: Q2 2024 in Review
5 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q2 2024, worth a combined $78.3K — up 163% from $29.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DRMA and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $122K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $8.2K sold.
- 5 institutional investors held Dermata Therapeutics (DRMA) as of Q2 2024, down from 6 in Q1 2024.
- Funds reported $78.3K of Dermata Therapeutics stock for Q2 2024, up 163% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q2 2024 and 3 closed out, a net change of -1 holder.
- The largest Dermata Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $122K added.
- The largest Dermata Therapeutics seller in Q2 2024 was Two Sigma Securities, an estimated $8.2K sold.
Based on aggregated 13F filings for Q2 2024.